SHTDY vs ARWR
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SHTDY · SINOPHARM GROUP CO$10.65 ▼ 0.47%
ARWR · Arrowhead Pharmaceuticals$41.37 ▼ 5.22%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SHTDY -14.2%
- ARWR -6.5%
Head to head
| Metric | SHTDY | ARWR |
|---|---|---|
| Price | $10.65 | $41.37 |
| Change today | ▼ 0.47% | ▼ 5.22% |
| Market cap | $5.84B | $5.85B |
| Return, 3 months | +2.8% | -52.3% |
| Return, year to date | -9.7% | -37.7% |
| Return, 1 year | -13.4% | +2.3% |
| P/E (TTM) | 6.6 | – |
| P/B | 0.5 | 116.2 |
| P/E percentile vs own 5y | – | 73rd |
| Dividend yield | 4.72% | – |
| Revenue growth (YoY, latest qtr) | – | -85.3% |
| Net profit growth (YoY) | – | -2,760.4% |
| Gross margin | – | 99.6% |
| Operating margin | – | -156.9% |
| Net margin | – | -160.6% |
| Return on equity | – | -280.5% |
| Analyst target vs. price | – | +157.7% |
| Analyst buy share | – | 91% |
| RSI (14) | 58 | 21 |
| 30-day volatility | 24.2% | 64.5% |
| Max drawdown, 1 year | -30.2% | -53.8% |
| Trend read | Leaning bullish | Strong downtrend |
| Analyst consensus | – | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ARWR is the largest of the group by market value.
- ARWR has returned the most over the past year.
- SHTDY has been the calmest stock over the last 30 days.